Anixa Biosciences (ANIX) vs Equillium (EQ)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Equillium (EQ) has outperformed Anixa Biosciences (ANIX) over the past year, gaining 17.2% versus a loss of 37.2%. Over five years, ANIX leads with a -34.6% price change compared with -74.4% for EQ. Anixa Biosciences is the larger company by market cap ($98.7 million vs $95.1 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANIX | EQ |
|---|---|---|
| Share price | $2.84 | $1.50 |
| Market cap | $98.73M | $95.11M |
| 1-day change | -2.07% | +6.38% |
| YTD return | -8.97% | -3.23% |
| 1-year return | -37.17% | +17.19% |
| 5-year return | -34.56% | -74.40% |
| EPS (TTM) | $-0.32 | $-0.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.46 | $3.54 |
| 52-week low | $2.32 | $0.76 |
| Distance from 52-week high | -47.99% | -57.63% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +243.31% | +470.67% |
| Average volume | 303.35K | 564.39K |
| Shares outstanding | 34.76M | 63.41M |
| Employees | 4 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EQ has outperformed ANIX by 54.4 percentage points over the past year.
About Anixa Biosciences
ANIX stock →Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
About Equillium
EQ stock →Equillium, Inc., a clinical-stage biotechnology company, develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders in the United States. The company develops EQ504, a novel AhR modulator that is in preclinical-stage for the treatment of ulcerative colitis and lung inflammation diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
ANIX vs EQ FAQ
Which is bigger, Anixa Biosciences or Equillium?
Anixa Biosciences (ANIX) is larger, with a market capitalization of $98.73M compared with $95.11M for Equillium (EQ).
Which stock has performed better over the past year, ANIX or EQ?
EQ returned +17.19% over the past 12 months, compared with -37.17% for ANIX (price return, excluding dividends). Past performance does not predict future results.
Are Anixa Biosciences and Equillium in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.